Teva Pharmaceutical Industries annual debt-to-assets ratio
2008
2009
2010
2011
2012
2013
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Teva Pharmaceutical Industries Debt-to-Assets Ratio Growth & History (TEVA)
Teva Pharmaceutical Industries's debt-to-assets ratio was 0.06 for fiscal 2025.
View full Teva Pharmaceutical Industries company overviewTeva Pharmaceutical Industries annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.06 | −0.00 | −0.93% |
| 2024 | 2024-12-31 | 0.06 | 0.01 | +14.00% |
| 2023 | 2023-12-31 | 0.05 | −0.01 | −16.56% |
| 2022 | 2022-12-31 | 0.06 | 0.02 | +41.03% |
| 2021 | 2021-12-31 | 0.04 | −0.03 | −44.81% |
| 2020 | 2020-12-31 | 0.08 | 0.02 | +47.49% |
| 2019 | 2019-12-31 | 0.05 | 0.01 | +39.47% |
| 2018 | 2018-12-31 | 0.04 | −0.37 | −91.06% |
| 2017 | 2017-12-31 | 0.41 | 0.06 | +16.76% |
| 2016 | 2016-12-31 | 0.35 | — | — |
| 2013 | 2013-12-31 | 0.24 | −0.04 | −15.62% |
| 2012 | 2012-12-31 | 0.28 | 0.05 | +22.98% |
| 2011 | 2011-12-31 | 0.23 | 0.19 | +499.96% |
| 2010 | 2010-12-31 | 0.04 | −0.01 | −14.78% |
| 2009 | 2009-12-31 | 0.04 | −0.10 | −69.05% |
| 2008 | 2008-12-31 | 0.14 | — | — |
Teva Pharmaceutical Industries quarterly debt-to-assets ratio
Q4.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
As of Dec 31, 2014
As of Mar 31, 2015
As of Jun 30, 2015
As of Sep 30, 2015
As of Dec 31, 2015
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.12 | 0.10 | +533.54% |
| Q1 2026 | 2026-03-31 | 0.07 | 0.05 | +291.34% |
| Q4 2025 | 2025-12-31 | 0.06 | −0.00 | −0.93% |
| Q3 2025 | 2025-09-30 | 0.01 | −0.06 | −88.81% |
| Q2 2025 | 2025-06-30 | 0.02 | −0.04 | −67.04% |
| Q1 2025 | 2025-03-31 | 0.02 | −0.06 | −76.46% |
| Q4 2024 | 2024-12-31 | 0.06 | 0.01 | +14.00% |
| Q3 2024 | 2024-09-30 | 0.07 | 0.03 | +60.74% |
| Q2 2024 | 2024-06-30 | 0.06 | 0.00 | +6.83% |
| Q1 2024 | 2024-03-31 | 0.08 | 0.05 | +149.12% |
| Q4 2023 | 2023-12-31 | 0.05 | −0.01 | −16.56% |
| Q3 2023 | 2023-09-30 | 0.04 | −0.03 | −39.31% |
| Q2 2023 | 2023-06-30 | 0.05 | 0.01 | +18.20% |
| Q1 2023 | 2023-03-31 | 0.03 | −0.02 | −40.03% |
| Q4 2022 | 2022-12-31 | 0.06 | 0.02 | +41.03% |
| Q3 2022 | 2022-09-30 | 0.07 | 0.01 | +7.75% |
| Q2 2022 | 2022-06-30 | 0.05 | −0.04 | −43.67% |
| Q1 2022 | 2022-03-31 | 0.05 | −0.01 | −18.03% |
| Q4 2021 | 2021-12-31 | 0.04 | −0.03 | −44.81% |
| Q3 2021 | 2021-09-30 | 0.07 | 0.01 | +26.36% |
| Q2 2021 | 2021-06-30 | 0.08 | 0.04 | +115.33% |
| Q1 2021 | 2021-03-31 | 0.06 | 0.03 | +73.60% |
| Q4 2020 | 2020-12-31 | 0.08 | 0.02 | +47.49% |
| Q3 2020 | 2020-09-30 | 0.05 | −0.01 | −19.13% |
| Q2 2020 | 2020-06-30 | 0.04 | −0.02 | −33.33% |
| Q1 2020 | 2020-03-31 | 0.04 | −0.02 | −34.17% |
| Q4 2019 | 2019-12-31 | 0.05 | 0.01 | +39.47% |
| Q3 2019 | 2019-09-30 | 0.06 | 0.02 | +56.00% |
| Q2 2019 | 2019-06-30 | 0.06 | 0.04 | +196.54% |
| Q1 2019 | 2019-03-31 | 0.06 | 0.04 | +197.75% |
| Q4 2018 | 2018-12-31 | 0.04 | −0.37 | −91.06% |
| Q3 2018 | 2018-09-30 | 0.04 | −0.33 | −88.94% |
| Q2 2018 | 2018-06-30 | 0.02 | −0.37 | −95.17% |
| Q1 2018 | 2018-03-31 | 0.02 | −0.34 | −94.77% |
| Q4 2017 | 2017-12-31 | 0.41 | 0.06 | +16.76% |
| Q3 2017 | 2017-09-30 | 0.37 | 0.04 | +10.54% |
| Q2 2017 | 2017-06-30 | 0.39 | 0.25 | +183.12% |
| Q1 2017 | 2017-03-31 | 0.36 | 0.20 | +129.44% |
| Q4 2016 | 2016-12-31 | 0.35 | 0.19 | +124.87% |
| Q3 2016 | 2016-09-30 | 0.34 | 0.29 | +660.61% |
| Q2 2016 | 2016-06-30 | 0.14 | 0.08 | +131.26% |
| Q1 2016 | 2016-03-31 | 0.16 | 0.12 | +352.83% |
| As of Dec 31, 2015 | 2015-12-31 | 0.16 | −0.03 | −16.19% |
| As of Sep 30, 2015 | 2015-09-30 | 0.04 | 0.00 | +12.39% |
| As of Jun 30, 2015 | 2015-06-30 | 0.06 | 0.02 | +36.90% |
| As of Mar 31, 2015 | 2015-03-31 | 0.03 | 0.00 | +4.64% |
| As of Dec 31, 2014 | 2014-12-31 | 0.19 | −0.05 | −21.33% |
| Q3 2014 | 2014-09-30 | 0.04 | −0.01 | −25.84% |
| Q2 2014 | 2014-06-30 | 0.04 | −0.01 | −17.85% |
| Q1 2014 | 2014-03-31 | 0.03 | −0.02 | −41.51% |
| Q4 2013 | 2013-12-31 | 0.24 | −0.04 | −15.62% |
| Q3 2013 | 2013-09-30 | 0.05 | 0.04 | +360.19% |
| Q2 2013 | 2013-06-30 | 0.05 | 0.04 | +193.31% |
| Q1 2013 | 2013-03-31 | 0.06 | −0.02 | −25.51% |
| Q4 2012 | 2012-12-31 | 0.28 | 0.05 | +22.98% |
| Q3 2012 | 2012-09-30 | 0.01 | −0.07 | −85.52% |
| Q2 2012 | 2012-06-30 | 0.02 | −0.03 | −62.10% |
| Q1 2012 | 2012-03-31 | 0.08 | 0.04 | +122.36% |
| Q4 2011 | 2011-12-31 | 0.23 | 0.19 | +499.96% |
| Q3 2011 | 2011-09-30 | 0.08 | 0.05 | +184.83% |
| Q2 2011 | 2011-06-30 | 0.05 | −0.01 | −14.16% |
| Q1 2011 | 2011-03-31 | 0.03 | −0.03 | −42.44% |
| Q4 2010 | 2010-12-31 | 0.04 | −0.01 | −14.78% |
| Q3 2010 | 2010-09-30 | 0.03 | −0.04 | −59.72% |
| Q2 2010 | 2010-06-30 | 0.06 | −0.03 | −37.59% |
| Q1 2010 | 2010-03-31 | 0.06 | −0.08 | −58.07% |
| Q4 2009 | 2009-12-31 | 0.04 | −0.10 | −69.05% |
| Q3 2009 | 2009-09-30 | 0.07 | — | — |
| Q2 2009 | 2009-06-30 | 0.09 | — | — |
| Q1 2009 | 2009-03-31 | 0.14 | — | — |
| Q4 2008 | 2008-12-31 | 0.14 | — | — |
Teva Pharmaceutical Industries debt-to-assets ratio trends
Over the last five fiscal years, Teva Pharmaceutical Industries's debt-to-assets ratio decreased from 0.08 to 0.06, a change of −0.02. The latest reported quarter, Q2 2026, shows 0.12.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Teva Pharmaceutical Industries source filings ↗